Overview
CELC market data
Price History
CELC price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for CELC. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the FirmGlobenewswire Inc · Jul 21, 2026, 10:00 PM
8-K/A filing — Celcuity Inc. (CELC)SEC EDGAR · Jul 15, 2026, 8:05 PM
Celcuity shares are trading lower after the company delayed the commercial launch of its newly approved breast cancer drug.Benzinga · Jul 15, 2026, 5:52 PM
Citizens Maintains Market Outperform on Celcuity, Raises Price Target to $177Benzinga · Jul 15, 2026, 1:34 PM
CrowdStrike To Rally Over 12%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · Jul 15, 2026, 1:06 PM
HC Wainwright & Co. Maintains Buy on Celcuity, Raises Price Target to $155Benzinga · Jul 15, 2026, 10:18 AM
8-K filing — Celcuity Inc. (CELC)SEC EDGAR · Jul 14, 2026, 9:39 PM
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast CancerGlobenewswire Inc · Jul 14, 2026, 9:15 PM
FDA Approves Gedatolisib With Fulvestrant, With Or Without Palbociclib, For Hr-Positive, Her2-Negative Locally Advanced Or Metastatic Breast CancerBenzinga · Jul 14, 2026, 7:27 PM
Craig-Hallum Maintains Buy on Celcuity, Lowers Price Target to $171Benzinga · Jun 3, 2026, 5:40 PM